Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry

Ján Stariat, Petra Kovaříková, Radim Kučera, Jiří Klimeš, Danuta S. Kalinowski, Des R. Richardson, Raimo A. Ketola

. 2013 ; 405 (5) : 1651-1661.

Language English Country Germany

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT12403 MZ0 CEP Register

Digital library NLK
Full text - Část
Source

E-resources Online Full text

NLK ProQuest Central from 2013-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2013-01-01 to 1 year ago

Di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) is a promising analogue of the dipyridyl thiosemicarbazone class currently under development as a potential anti-cancer drug. In fact, this class of agents shows markedly greater anti-tumor activity and selectivity than the clinically investigated thiosemicarbazone, Triapine®. However, further development of DpC requires detailed data concerning its metabolism. Therefore, we focused on the identification of principal phase I and II metabolites of DpC in vitro. DpC was incubated with human liver microsomes/S9 fractions and the samples were analyzed using ultra-performance liquid chromatography (UPLC(TM)) with electrospray ionization quadrupole-time-of-flight (Q-TOF) mass spectrometry. An Acquity UPLC BEH C(18) column was implemented with 2 mM ammonium acetate and acetonitrile in gradient mode as the mobile phase. The chemical structures of metabolites were proposed based on the accurate mass measurement of the protonated molecules as well as their main product ions. Ten phase I and two phase II metabolites were detected and structurally described. The metabolism of DpC occurred via oxidation of the thiocarbonyl group, hydroxylation and N-demethylation, as well as the combination of these reactions. Conjugates of DpC and the metabolite, M10, with glucuronic acid were also observed as phase II metabolites. Neither sulfate nor glutathione conjugates were detected. This study provides the first information about the chemical structure of the principal metabolites of DpC, which supports the development of this promising anti-cancer drug and provides vital data for further pharmacokinetic and in vivo metabolism studies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031807
003      
CZ-PrNML
005      
20170411114435.0
007      
ta
008      
131002s2013 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00216-012-6562-x $2 doi
035    __
$a (PubMed)23180090
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Stariat, Ján $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
245    10
$a Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry / $c Ján Stariat, Petra Kovaříková, Radim Kučera, Jiří Klimeš, Danuta S. Kalinowski, Des R. Richardson, Raimo A. Ketola
520    9_
$a Di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) is a promising analogue of the dipyridyl thiosemicarbazone class currently under development as a potential anti-cancer drug. In fact, this class of agents shows markedly greater anti-tumor activity and selectivity than the clinically investigated thiosemicarbazone, Triapine®. However, further development of DpC requires detailed data concerning its metabolism. Therefore, we focused on the identification of principal phase I and II metabolites of DpC in vitro. DpC was incubated with human liver microsomes/S9 fractions and the samples were analyzed using ultra-performance liquid chromatography (UPLC(TM)) with electrospray ionization quadrupole-time-of-flight (Q-TOF) mass spectrometry. An Acquity UPLC BEH C(18) column was implemented with 2 mM ammonium acetate and acetonitrile in gradient mode as the mobile phase. The chemical structures of metabolites were proposed based on the accurate mass measurement of the protonated molecules as well as their main product ions. Ten phase I and two phase II metabolites were detected and structurally described. The metabolism of DpC occurred via oxidation of the thiocarbonyl group, hydroxylation and N-demethylation, as well as the combination of these reactions. Conjugates of DpC and the metabolite, M10, with glucuronic acid were also observed as phase II metabolites. Neither sulfate nor glutathione conjugates were detected. This study provides the first information about the chemical structure of the principal metabolites of DpC, which supports the development of this promising anti-cancer drug and provides vital data for further pharmacokinetic and in vivo metabolism studies.
650    _2
$a protinádorové látky $x chemie $x metabolismus $7 D000970
650    _2
$a vysokoúčinná kapalinová chromatografie $x metody $7 D002851
650    _2
$a lidé $7 D006801
650    _2
$a jaterní mikrozomy $x metabolismus $7 D008862
650    _2
$a tandemová hmotnostní spektrometrie $x metody $7 D053719
650    _2
$a thiosemikarbazony $x chemie $x metabolismus $7 D013882
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kovaříková, Petra $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
700    1_
$a Kučera, Radim $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
700    1_
$a Klimeš, Jiří $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
700    1_
$a Kalinowski, Danuta S. $u Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW, Australia
700    1_
$a Richardson, Des R. $u Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW, Australia
700    1_
$a Ketola, Raimo A. $u Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
773    0_
$w MED00006638 $t Analytical and bioanalytical chemistry $x 1618-2650 $g Roč. 405, č. 5 (2013), s. 1651-1661
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23180090 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20170411114734 $b ABA008
999    __
$a ok $b bmc $g 995894 $s 830252
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 405 $c 5 $d 1651-1661 $i 1618-2650 $m Analytical and bioanalytical chemistry $n Anal Bioanal Chem $x MED00006638
GRA    __
$a NT12403 $p MZ0
LZP    __
$a Pubmed-20131002

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...